$80.000
-2.424 (-3.03%)Zum Schluss
GRAL-News
GRAL-Events
GRAIL's Galleri Test Application to be Reviewed by FDA on Sept. 23
GRAIL announced that the U.S. Food and Drug Administration's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23 to review the Premarket Approval application for the Galleri multi-cancer early detection blood test.The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommended screening today. When a cancer signal is detected, Galleri is designed to predict the cancer signal origin with high accuracy to help guide diagnostic evaluation. The test is intended to be used in addition to, and not as a replacement for, guideline-recommended screenings.
Grail Partners with Priority Health to Launch Galleri Multi-Cancer Early Detection
Grail announced a collaboration with Priority Health, a nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make Grail's Galleri multi-cancer early detection - or MCED - test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025 and is expanding on its partnership with Grail to become the first Michigan health plan to enable its employer groups to easily add the Galleri test to their existing cancer screening coverage. Priority Health is a nonprofit health plan serving more than 1.4 million members across Michigan and beyond. With a simple blood draw, Galleri screens for many of the deadliest cancers before symptoms appear.
Grail Shares Drop 15.6% to $60.47
Grail is down -15.6%, or -$11.21 to $60.47.
Grail Shares Drop 18.4% to $58.50
Grail is down -18.4%, or -$13.18 to $58.50.
GRAIL Presents NHS-Galleri Trial Results at ASCO Meeting
GRAIL announced detailed clinical utility, performance and safety results from its NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting. Key highlights: No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round; Annual Galleri Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively; Galleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%; Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of Care
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.